Colistin Resistance & Virulence: A. baumannii PmrB Mutation

The escalating threat of carbapenem-resistant Acinetobacter baumannii (CRAB) isn’t just a clinical problem; it’s a stark warning about the limits of our antibiotic arsenal and the speed at which bacteria are evolving resistance. Recent research, culminating in publications throughout 2021-2025 (Russo & Serapide, 2025; Jiang et al., 2022), paints a concerning picture of increasing CRAB prevalence, particularly in intensive care units, and highlights the complex mechanisms driving this resistance. This isn’t a future problem – the CDC already flagged CRAB as an urgent public health threat in 2021 (CDC, 2021).

The core issue lies in the bacterium’s remarkable ability to adapt. CRAB’s resistance isn’t just about acquiring new genes; it’s about modifying existing ones and activating alternative pathways. The PmrA/B system, for example, regulates modifications to lipid A, a crucial component of the bacterial outer membrane, reducing the effectiveness of polymyxins (Lee et al., 2004; Tamayo et al., 2002). Recent studies (Butters et al., 2024; Shahab et al., 2024) are revealing that specific mutations in PmrB aren’t always directly linked to colistin resistance but are strongly associated with bacterial phylogeny, suggesting a complex evolutionary history. Furthermore, the emergence of mobile genetic elements like IS Ajo2 and IS Aba13 (Chamoun et al., 2021) facilitates the spread of resistance genes, accelerating the problem. The situation is compounded by the fact that CRAB can thrive in hospital environments, colonizing patients and spreading through contact (Cogliati Dezza et al., 2023).

The geographical distribution of CRAB and the specific resistance mechanisms vary. Studies from Bahrain (Al-Rashed et al., 2023) and Iraq (Wajid Odhafa et al., 2024) highlight the prevalence of OXA-23 carbapenemases, while research in India (Halder et al., 2025) demonstrates the concurrent transmission of mcr-9 and carbapenemase genes. This underscores the need for localized surveillance and tailored infection control strategies. It’s also important to note that resistance isn’t limited to antibiotics; some strains are showing reduced susceptibility to disinfectants like chlorhexidine (Tozluyurt, 2024), further complicating infection prevention efforts.

The Forward Look: The trajectory is clear: without intervention, CRAB will become increasingly difficult, and potentially impossible, to treat. The immediate future will likely see a greater emphasis on several key areas. First, expect increased investment in rapid diagnostic tools to quickly identify CRAB and its resistance profile. Machine learning approaches (Wang et al., 2022) are already being explored for predicting patient mortality based on infection data, and these could be adapted for earlier CRAB detection. Second, research into novel antimicrobial agents is critical, but the pipeline is notoriously slow. Combination therapies, leveraging existing antibiotics with efflux pump inhibitors or other potentiators, offer a more immediate, albeit temporary, solution. Finally, and perhaps most importantly, a renewed focus on antimicrobial stewardship and infection prevention practices is essential. This includes rigorous hand hygiene, environmental disinfection, and patient isolation protocols. The emergence of resistance is an evolutionary arms race, and we are currently losing ground. The next few years will determine whether we can regain the initiative, or face a future where common infections once again become life-threatening.